Boston Scientific (BSX) Total Non-Current Liabilities (2009 - 2026)

Boston Scientific has disclosed Total Non-Current Liabilities across 18 years of filings, most recently posting $15.8 billion for Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $15.8 billion, changed 0.19% year-over-year; the trailing twelve-month figure through Mar 2026 was $15.8 billion (changed 0.19% YoY), and the FY2025 annual result was $16.8 billion, up 6.61% from the prior year.
• Total Non-Current Liabilities came in at $15.8 billion for Q1 2026 at Boston Scientific, down from $16.8 billion in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $35.3 billion in Q2 2024 to a low of $10.1 billion in Q2 2022.
• The 5-year median for Total Non-Current Liabilities is $16.7 billion (2025), against an average of $21.1 billion.
• Across the five-year window, Total Non-Current Liabilities slumped 65.13% in 2022 and soared 211.11% in 2023, its largest moves.
• Boston Scientific's Total Non-Current Liabilities stood at $30.2 billion in 2022, then sank by 54.79% to $13.6 billion in 2023, then rose by 15.51% to $15.8 billion in 2024, then gained by 6.61% to $16.8 billion in 2025, then fell by 6.06% to $15.8 billion in 2026.
• The last three Total Non-Current Liabilities figures came in at $15.8 billion (Q1 2026), $16.8 billion (Q4 2025), and $16.7 billion (Q3 2025), per Business Quant data.